Duality Biotherapeutics Stock: Overvalued Despite 50% Price Drop
Duality Biotherapeutics (SEHK:9606) trades at a significant market premium despite a 50.2% share price decline over the past year. While a recent licensing collaboration with Genentech validates its DUPAC antibody-drug … Read More